(NASDAQ: ZNTL) Zentalis Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 43.76%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.65%.
Zentalis Pharmaceuticals's earnings in 2025 is -$149,316,000.On average, 11 Wall Street analysts forecast ZNTL's earnings for 2025 to be -$134,400,899, with the lowest ZNTL earnings forecast at -$138,071,239, and the highest ZNTL earnings forecast at -$125,174,475. On average, 11 Wall Street analysts forecast ZNTL's earnings for 2026 to be -$124,639,819, with the lowest ZNTL earnings forecast at -$160,729,083, and the highest ZNTL earnings forecast at -$98,622,313.
In 2027, ZNTL is forecast to generate -$119,387,187 in earnings, with the lowest earnings forecast at -$155,064,622 and the highest earnings forecast at -$78,897,851.